Tanvex BioPharma Inc
Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that… Read more
Tanvex BioPharma Inc (6541) - Net Assets
Latest net assets as of September 2025: NT$6.00 Billion TWD
Based on the latest financial reports, Tanvex BioPharma Inc (6541) has net assets worth NT$6.00 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$8.18 Billion) and total liabilities (NT$2.17 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$6.00 Billion |
| % of Total Assets | 73.41% |
| Annual Growth Rate | 7.49% |
| 5-Year Change | -65.91% |
| 10-Year Change | -38.31% |
| Growth Volatility | 64.07 |
Tanvex BioPharma Inc - Net Assets Trend (2013–2024)
This chart illustrates how Tanvex BioPharma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tanvex BioPharma Inc (2013–2024)
The table below shows the annual net assets of Tanvex BioPharma Inc from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$893.31 Million | +8.79% |
| 2023-12-31 | NT$821.11 Million | -40.99% |
| 2022-12-31 | NT$1.39 Billion | -50.21% |
| 2021-12-31 | NT$2.79 Billion | +6.64% |
| 2020-12-31 | NT$2.62 Billion | -13.53% |
| 2019-12-31 | NT$3.03 Billion | -28.09% |
| 2018-12-31 | NT$4.21 Billion | +12.42% |
| 2017-12-31 | NT$3.75 Billion | +4.93% |
| 2016-12-31 | NT$3.57 Billion | +146.76% |
| 2015-12-31 | NT$1.45 Billion | +145.57% |
| 2014-12-31 | NT$589.64 Million | +46.08% |
| 2013-12-31 | NT$403.64 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tanvex BioPharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1406434000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$1.64 Billion | 183.67% |
| Other Comprehensive Income | NT$-177.94 Million | -19.92% |
| Other Components | NT$13.57 Billion | 1518.74% |
| Total Equity | NT$893.31 Million | 100.00% |
Tanvex BioPharma Inc Competitors by Market Cap
The table below lists competitors of Tanvex BioPharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Probi AB
ST:PROB
|
$106.63 Million |
|
Wireless Power Amplifier Module Inc
KQ:332570
|
$106.65 Million |
|
Benchmark Bankshares Inc
PINK:BMBN
|
$106.67 Million |
|
Grupo Gicsa S.A. de C.V
MX:GICSAB
|
$106.68 Million |
|
Sapura Energy Bhd
KLSE:5218
|
$106.55 Million |
|
B Communications Ltd
PINK:BCOMF
|
$106.54 Million |
|
Polight ASA
OL:PLT
|
$106.53 Million |
|
vTv Therapeutics Inc
NASDAQ:VTVT
|
$106.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tanvex BioPharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 821,110,000 to 893,306,000, a change of 72,196,000 (8.8%).
- Net loss of 1,381,550,000 reduced equity.
- New share issuances of 1,439,668,000 increased equity.
- Other comprehensive income decreased equity by 1,126,965,000.
- Other factors increased equity by 1,141,043,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-1.38 Billion | -154.66% |
| Share Issuances | NT$1.44 Billion | +161.16% |
| Other Comprehensive Income | NT$-1.13 Billion | -126.16% |
| Other Changes | NT$1.14 Billion | +127.73% |
| Total Change | NT$- | 8.79% |
Book Value vs Market Value Analysis
This analysis compares Tanvex BioPharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.32x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.14x to 7.32x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | NT$13.42 | NT$42.10 | x |
| 2014-12-31 | NT$16.95 | NT$42.10 | x |
| 2015-12-31 | NT$28.98 | NT$42.10 | x |
| 2016-12-31 | NT$53.26 | NT$42.10 | x |
| 2017-12-31 | NT$54.94 | NT$42.10 | x |
| 2018-12-31 | NT$52.80 | NT$42.10 | x |
| 2019-12-31 | NT$34.87 | NT$42.10 | x |
| 2020-12-31 | NT$28.16 | NT$42.10 | x |
| 2021-12-31 | NT$24.99 | NT$42.10 | x |
| 2022-12-31 | NT$11.49 | NT$42.10 | x |
| 2023-12-31 | NT$6.31 | NT$42.10 | x |
| 2024-12-31 | NT$5.75 | NT$42.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tanvex BioPharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -154.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3983.94%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 3.06x
- Recent ROE (-154.66%) is below the historical average (-89.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -74.08% | 0.00% | 0.00x | 1.21x | NT$-339.40 Million |
| 2014 | -80.13% | 0.00% | 0.00x | 1.11x | NT$-531.45 Million |
| 2015 | -57.68% | 0.00% | 0.00x | 1.08x | NT$-980.05 Million |
| 2016 | -34.83% | 0.00% | 0.00x | 1.08x | NT$-1.60 Billion |
| 2017 | -37.60% | 0.00% | 0.00x | 1.06x | NT$-1.78 Billion |
| 2018 | -44.93% | 0.00% | 0.00x | 1.06x | NT$-2.32 Billion |
| 2019 | -75.04% | 0.00% | 0.00x | 1.18x | NT$-2.58 Billion |
| 2020 | -80.29% | -701412.00% | 0.00x | 1.67x | NT$-2.37 Billion |
| 2021 | -55.22% | -28546.26% | 0.00x | 1.69x | NT$-1.82 Billion |
| 2022 | -117.94% | -7325.17% | 0.01x | 2.46x | NT$-1.78 Billion |
| 2023 | -260.27% | -3480.00% | 0.02x | 3.37x | NT$-2.22 Billion |
| 2024 | -154.66% | -3983.94% | 0.01x | 3.06x | NT$-1.47 Billion |
Industry Comparison
This section compares Tanvex BioPharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tanvex BioPharma Inc (6541) | NT$6.00 Billion | -74.08% | 0.36x | $106.58 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |